Compare Citius Pharmaceuticals Inc (CTXR) vs iShares MSCI South Korea ETF (EWY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs iShares MSCI South Korea ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while iShares MSCI South Korea ETF trades at $177.29 (market cap $26.25B). The key difference: iShares MSCI South Korea ETF is far larger — about 1927.3× Citius Pharmaceuticals Inc's market cap, and iShares MSCI South Korea ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and iShares MSCI South Korea ETF for 47 Days on average.
| CTXR | EWY | |
|---|---|---|
Market Cap | $13.62M | $26.25B |
Volume | 132,438 | 19,056,075 |
Sector | Health | Broad Market / Factor |
52-Week High | $1.82 | $219.20 |
52-Week Low | $0.48 | $80.72 |
Typical Hold Time | 17 Days | 47 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
EWY (iShares MSCI South Korea ETF) is trading at $177.18, down 3.56% amid broad Asian market weakness driven by rising oil prices and global bond yields. The ETF shows a bearish technical signal with moving averages indicating selling pressure, though RSI levels suggest potential oversold conditions. Recent news highlights South Korea's KOSPI volatility, with semiconductor stocks facing pressure despite strong AI demand fundamentals and corporate earnings resilience.
The outlook remains cautious due to concentrated exposure to Samsung and SK hynix, making EWY highly sensitive to memory cycle trends. While AI infrastructure spending provides long-term growth potential, near-term risks include rising borrowing costs, oil price volatility, and geopolitical tensions. The ETF's heavy technology weighting creates both opportunity and vulnerability to sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →
